Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.
Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.
Curr Opin Immunol. 2018 Aug;53:81-87. doi: 10.1016/j.coi.2018.04.012. Epub 2018 Apr 25.
How are lymphatic vessels built? What are the sources of progenitor cells employed to construct lymphatic vessels during embryogenesis and in pathological situations? Are lymphatic vessels in different tissues built the same way? These questions have been highly topical and actively debated in the field of lymphangiogenesis research for more than 100 years. While embryonic veins and cells of mesenchymal origin have been recognised as sources of embryonic lymphatic endothelial cells for many years, recent advances in technology have revealed the existence of additional sources of lymphatic endothelial cells important for embryonic lymphangiogenesis. Intriguingly, distinct progenitor cell sources appear to be employed in a tissue specific manner during development. Gaining further insight into the identity of lymphatic endothelial progenitor cells and the signals that direct their assembly, both during development and in disease, has the potential to enable the design of therapeutics able to selectively target specific lymphatic vessel beds, a feature likely to prove valuable for the treatment of human disorders including cancer, lymphoedema and inflammatory disease.
淋巴管是如何形成的?在胚胎发生和病理情况下,构建淋巴管所使用的祖细胞的来源是什么?不同组织中的淋巴管是否以相同的方式构建?这些问题在淋巴管生成研究领域已经成为热门话题,并引发了激烈的争论,已经有 100 多年的历史了。虽然胚胎静脉和间充质来源的细胞多年来一直被认为是胚胎淋巴管内皮细胞的来源,但最近技术的进步揭示了存在其他对胚胎淋巴管生成很重要的淋巴管内皮细胞的来源。有趣的是,在发育过程中,不同的祖细胞来源似乎以组织特异性的方式被利用。进一步深入了解淋巴管内皮祖细胞的特性以及指导其在发育和疾病过程中组装的信号,有可能设计出能够选择性靶向特定淋巴管床的治疗方法,这一特性对于治疗包括癌症、淋巴水肿和炎症性疾病在内的人类疾病可能具有重要价值。